trending Market Intelligence /marketintelligence/en/news-insights/trending/qh1cznohc8tznke1swweza2 content esgSubNav
In This List

Jaguar Health attracts private equity investment

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


Jaguar Health attracts private equity investment

San Francisco's Jaguar Health Inc. agreed to issue 5,524,926 preferred shares in a private placement to Sagard Capital Partners LP, a private equity firm.

The company, which develops gastrointestinal therapies for humans and animals, expects to raise about $9.2 million through the placement.

Proceeds will go toward commercializing Jaguar Health's Mytesi, an anti-diarrheal drug for HIV/AIDS patients, and general corporate purposes.

Each preferred share is convertible into common shares of the company.

Sagard Capital Partners may also elect two directors to Jaguar Health's board under certain circumstances. To that end, Jaguar Health has already appointed Jeffrey Johnson to its board.

Johnson is a partner at Sagard Holdings ULC and an investment manager at Sagard Capital Partners Management Corp.

Concurrently, Jaguar Health issued $5 million worth of common shares at 17 cents each to certain institutional investors. The company said it will use proceeds to repay certain fees relating to its acquisition of Napo Pharmaceuticals Inc. in July 2017.